vigabatrin has been researched along with Spasm in 23 studies
Spasm: An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This systematic review and meta-analysis aimed to evaluate the efficacy of vigabatrin (VGB) in treating infantile epileptic spasms syndrome (IESS)." | 9.41 | Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. ( Chang, X; Gong, P; Jiao, X; Niu, Y; Wu, Y; Xu, Z; Yang, Z; Zhang, Y, 2023) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 8.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "To report response to first treatment in infants with infantile spasms (IS), including incremental benefit of prednisolone 60 mg/day and vigabatrin following prednisolone 40 mg/day failure in infants commenced on the United Kingdom Infantile Spasms Study (UKISS) treatment sequence." | 8.12 | Response to sequential treatment with prednisolone and vigabatrin in infantile spasms. ( Cheng, S; Dzau, W; Fahey, M; Harvey, AS; Howell, KB; Scheffer, IE; Snell, P, 2022) |
| "Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS)." | 8.02 | What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? ( Arbour, M; Bello-Espinosa, L; Birca, A; Bitton, JY; Desnous, B; Lenoir, M; Lortie, A; Mohammed, I; Ronen, GM; Villeneuve, N; Whiting, S; Wirrell, EC, 2021) |
| "This systematic review and meta-analysis aimed to evaluate the efficacy of vigabatrin (VGB) in treating infantile epileptic spasms syndrome (IESS)." | 5.41 | Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. ( Chang, X; Gong, P; Jiao, X; Niu, Y; Wu, Y; Xu, Z; Yang, Z; Zhang, Y, 2023) |
| "To describe the temporal trends in the cost and use of adrenocorticotropic hormone (ACTH), oral prednisolone, and vigabatrin, the first-line treatments for infantile epileptic spasms syndrome (IESS)." | 4.31 | Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome. ( Amengual-Gual, M; Barcia Aguilar, C; Chao, J; Douglass, L; Gaínza-Lein, M; Harini, C; Jonas, R; Romeu, A; Sánchez Fernández, I; Sheikh, T; Torres, A, 2023) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 4.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "We evaluated patients with ES from the CDKL5 Centers of Excellence and the National Infantile Spasms Consortium (NISC), with onset from 2 months to 2 years, treated with adrenocorticotropic hormone (ACTH), oral corticosteroids, vigabatrin, and/or the ketogenic diet." | 4.31 | Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies. ( Benke, T; Daniels, C; DeLeo, M; Demarest, S; Greene, C; Harini, C; Haviland, I; Katyayan, A; Love-Nichols, J; Marsh, ED; Moosa, AN; O'Connor Prange, E; Olson, HE; Pérez-Pérez, JR; Pestana-Knight, E; Poduri, A; Rajaraman, RR; Suter, B; Swanson, L; Weisenberg, J; Zhang, B; Zhang, X, 2023) |
| "Prednisolone is an effective and well-tolerated medication for treating infantile spasms in Down syndrome." | 4.12 | Response to treatment and outcomes of infantile spasms in Down syndrome. ( Allen, NM; Gorman, KM; Harvey, S; King, MD; Lynch, B; Lynch, SA; O'Regan, M; O'Rourke, D; Shahwan, A; Webb, D, 2022) |
| "To report response to first treatment in infants with infantile spasms (IS), including incremental benefit of prednisolone 60 mg/day and vigabatrin following prednisolone 40 mg/day failure in infants commenced on the United Kingdom Infantile Spasms Study (UKISS) treatment sequence." | 4.12 | Response to sequential treatment with prednisolone and vigabatrin in infantile spasms. ( Cheng, S; Dzau, W; Fahey, M; Harvey, AS; Howell, KB; Scheffer, IE; Snell, P, 2022) |
| "Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS)." | 4.02 | What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? ( Arbour, M; Bello-Espinosa, L; Birca, A; Bitton, JY; Desnous, B; Lenoir, M; Lortie, A; Mohammed, I; Ronen, GM; Villeneuve, N; Whiting, S; Wirrell, EC, 2021) |
| "To review the result of the infantile spasms' treatment with sodium valproate followed by nitrazepam or clonazepam." | 3.74 | Treatment of infantile spasms with sodium valproate followed by benzodiazepines. ( Auvichayapat, N; Auvichayapat, P; Tassniyom, S; Treerotphon, S, 2007) |
| "The first one is represented by West Syndrome (WS): ES occur in a previously non encephalopathic infant in association with the development of a hypsarrhythmic EEG pattern." | 2.66 | Three different scenarios for epileptic spasms. ( Fusco, L; Santarone, ME; Serino, D, 2020) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Epileptic spasms were asymmetric in three patients and unilateral in two." | 1.72 | Status of epileptic spasms: A study of 21 children. ( Buompadre, C; Caraballo, R; Chacón, S; Fasulo, L; Gallo, A; Reyes, G; Semprino, M, 2022) |
| "It has been known that West syndrome (WS) patients with an unknown etiology have better clinical outcomes than patients with an identified etiology of any kind." | 1.62 | Disparate treatment outcomes according to presence of pathogenic mutations in West syndrome. ( Choi, HS; Choi, JR; Kang, HC; Kim, HD; Kim, SH; Ko, A; Lee, JS; Lee, ST, 2021) |
| "In five cases, tonic seizures preceded spasms at a median age of 6 weeks." | 1.51 | New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. ( Bienvenu, T; Chikvinidze, G; Dulac, O; Epitashvili, N; Gataullina, S; Melikishvili, G; Tabatadze, N, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 15 (65.22) | 2.80 |
| Authors | Studies |
|---|---|
| Caraballo, R | 1 |
| Semprino, M | 1 |
| Fasulo, L | 1 |
| Reyes, G | 1 |
| Chacón, S | 1 |
| Gallo, A | 1 |
| Buompadre, C | 1 |
| Harvey, S | 1 |
| Allen, NM | 1 |
| King, MD | 1 |
| Lynch, B | 1 |
| Lynch, SA | 1 |
| O'Regan, M | 1 |
| O'Rourke, D | 1 |
| Shahwan, A | 1 |
| Webb, D | 1 |
| Gorman, KM | 1 |
| Barrett, KT | 1 |
| Choudhary, A | 1 |
| Charkhand, B | 1 |
| Scantlebury, MH | 1 |
| Dzau, W | 1 |
| Cheng, S | 1 |
| Snell, P | 1 |
| Fahey, M | 1 |
| Scheffer, IE | 1 |
| Harvey, AS | 1 |
| Howell, KB | 1 |
| Sánchez Fernández, I | 1 |
| Amengual-Gual, M | 1 |
| Barcia Aguilar, C | 1 |
| Romeu, A | 1 |
| Sheikh, T | 1 |
| Torres, A | 1 |
| Chao, J | 1 |
| Jonas, R | 1 |
| Gaínza-Lein, M | 1 |
| Harini, C | 2 |
| Douglass, L | 1 |
| Osborne, JP | 1 |
| Edwards, SW | 1 |
| Alber, FD | 1 |
| Hancock, E | 1 |
| Johnson, AL | 1 |
| Kennedy, CR | 1 |
| Likeman, M | 1 |
| Lux, AL | 1 |
| Mackay, M | 1 |
| Mallick, A | 1 |
| Newton, RW | 1 |
| Nolan, M | 1 |
| Pressler, R | 1 |
| Rating, D | 1 |
| Schmitt, B | 1 |
| Verity, CM | 1 |
| O'Callaghan, FK | 1 |
| Riikonen, R | 1 |
| Xu, Z | 1 |
| Gong, P | 1 |
| Jiao, X | 1 |
| Niu, Y | 1 |
| Wu, Y | 1 |
| Zhang, Y | 1 |
| Chang, X | 1 |
| Yang, Z | 1 |
| Olson, HE | 1 |
| Demarest, S | 1 |
| Pestana-Knight, E | 1 |
| Moosa, AN | 1 |
| Zhang, X | 1 |
| Pérez-Pérez, JR | 1 |
| Weisenberg, J | 1 |
| O'Connor Prange, E | 1 |
| Marsh, ED | 1 |
| Rajaraman, RR | 1 |
| Suter, B | 1 |
| Katyayan, A | 2 |
| Haviland, I | 1 |
| Daniels, C | 1 |
| Zhang, B | 1 |
| Greene, C | 1 |
| DeLeo, M | 1 |
| Swanson, L | 1 |
| Love-Nichols, J | 1 |
| Benke, T | 1 |
| Poduri, A | 1 |
| Takacs, DS | 1 |
| Vanderslice, K | 1 |
| Riviello, JJ | 1 |
| Lal, P | 1 |
| Sahu, JK | 1 |
| Sampaio, LPB | 1 |
| Henriques-Souza, AMM | 1 |
| Silveira, MRMD | 1 |
| Seguti, L | 1 |
| Santos, MLSF | 1 |
| Montenegro, MA | 1 |
| Antoniuk, S | 1 |
| Manreza, MLG | 1 |
| Fusco, L | 1 |
| Serino, D | 1 |
| Santarone, ME | 1 |
| Choi, HS | 1 |
| Ko, A | 1 |
| Kim, SH | 1 |
| Lee, ST | 1 |
| Choi, JR | 1 |
| Lee, JS | 1 |
| Kim, HD | 1 |
| Kang, HC | 1 |
| Desnous, B | 1 |
| Lenoir, M | 1 |
| Bitton, JY | 1 |
| Arbour, M | 1 |
| Villeneuve, N | 1 |
| Whiting, S | 1 |
| Mohammed, I | 1 |
| Wirrell, EC | 1 |
| Bello-Espinosa, L | 1 |
| Ronen, GM | 1 |
| Lortie, A | 1 |
| Birca, A | 1 |
| Zuberi, SM | 1 |
| Melikishvili, G | 1 |
| Epitashvili, N | 1 |
| Tabatadze, N | 1 |
| Chikvinidze, G | 1 |
| Dulac, O | 1 |
| Bienvenu, T | 1 |
| Gataullina, S | 1 |
| Jain, P | 1 |
| Alwadhi, R | 1 |
| Kumar, V | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Kölker, S | 1 |
| Hoffmann, GF | 1 |
| Schor, DS | 1 |
| Feyh, P | 1 |
| Wagner, L | 1 |
| Jeffrey, I | 1 |
| Pourfarzam, M | 1 |
| Okun, JG | 1 |
| Zschocke, J | 1 |
| Baric, I | 1 |
| Bain, MD | 1 |
| Jakobs, C | 1 |
| Chalmers, RA | 1 |
| Auvichayapat, N | 1 |
| Tassniyom, S | 1 |
| Treerotphon, S | 1 |
| Auvichayapat, P | 1 |
| Visudhiphan, P | 1 |
5 reviews available for vigabatrin and Spasm
| Article | Year |
|---|---|
Animal Models in Epileptic Spasms and the Development of Novel Treatment Options.
Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Electroencephalography; Humans; Models, Anima | 2022 |
Biochemical mechanisms in pathogenesis of infantile epileptic spasm syndrome.
Topics: Anticonvulsants; Epilepsy; Glucocorticoids; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2023 |
Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis.
Topics: Anticonvulsants; Humans; Spasm; Spasms, Infantile; Syndrome; Vigabatrin | 2023 |
Three different scenarios for epileptic spasms.
Topics: Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2020 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
18 other studies available for vigabatrin and Spasm
| Article | Year |
|---|---|
Status of epileptic spasms: A study of 21 children.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; | 2022 |
Response to treatment and outcomes of infantile spasms in Down syndrome.
Topics: Adult; Anticonvulsants; Child; Down Syndrome; Humans; Infant; Prednisolone; Seizures; Spasm; Spasms, | 2022 |
Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Prednisolone; Recurrence; Retrospective Studies; Spasm; Spasms, Inf | 2022 |
Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child; Female; Humans; Infant; Infant, Newborn; Male; | 2023 |
Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials.
Topics: Anticonvulsants; Cosyntropin; Epilepsy; Humans; Infant; Prednisolone; Randomized Controlled Trials a | 2023 |
Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Female; Humans; Infant; Male; | 2023 |
Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting.
Topics: Electroencephalography; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2023 |
What Should be the Next Choice After Failure of Hormonal and Vigabatrin Therapy in Infantile Epileptic Spasms Syndrome?
Topics: Anticonvulsants; Humans; Infant; Spasm; Spasms, Infantile; Syndrome; Treatment Outcome; Vigabatrin | 2023 |
Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.
Topics: Anticonvulsants; Brazil; Child; Consensus; Epilepsy; Humans; Infant; Prednisolone; Recurrence; Spasm | 2023 |
Disparate treatment outcomes according to presence of pathogenic mutations in West syndrome.
Topics: Age of Onset; Anti-Inflammatory Agents; Anticonvulsants; Arrhythmias, Cardiac; Child; Child, Prescho | 2021 |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?
Topics: Anticonvulsants; Child; Humans; Infant; Prospective Studies; Retrospective Studies; Spasm; Spasms, I | 2021 |
Precious time to respond to infantile spasms.
Topics: Adrenocorticotropic Hormone; Humans; Spasm; Spasms, Infantile; Vigabatrin | 2018 |
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
Reversible MRI Changes in an Infant with Epileptic Spasms on Low Dose Vigabatrin.
Topics: Anticonvulsants; Electroencephalography; Enzyme Inhibitors; Humans; Infant; Magnetic Resonance Imagi | 2016 |
Glutaryl-CoA dehydrogenase deficiency: region-specific analysis of organic acids and acylcarnitines in post mortem brain predicts vulnerability of the putamen.
Topics: Acidosis; Acute Disease; Adolescent; Anticonvulsants; Atrophy; Brain; Carnitine; DNA Mutational Anal | 2003 |
Treatment of infantile spasms with sodium valproate followed by benzodiazepines.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Benzodiazepines; Clonazepam; Drug Therapy, Combination | 2007 |
Treatment of infantile spasms with sodium valproate followed by benzodiazepines.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Benzodiazepines; Clonazepam; Drug Therapy, Combination | 2007 |
Visual field constriction on vigabatrin.
Topics: Adult; Anticonvulsants; Epilepsy; Europe; Humans; Infant; Spasm; Treatment Outcome; Tuberous Scleros | 2000 |